{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:30:06Z","timestamp":1787927406513,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cct.2025.108075","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:17:58Z","timestamp":1757096278000},"page":"108075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38\/CRUSH-TB design"],"prefix":"10.1016","volume":"158","author":[{"given":"Ekaterina V.","family":"Kurbatova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Stout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P.J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn M.","family":"Upton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ignatius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita M.","family":"Traxler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kia E.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith G.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rada","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Eichberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Hesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Bark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.","family":"Benator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Muzanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Twycross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Burzynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2025.108075_bb0005","first-page":"2024","author":"World Health Organization","year":"2024","journal-title":"Global TB Rep."},{"issue":"5","key":"10.1016\/j.cct.2025.108075_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103955","article-title":"Tuberculosis treatment-shortening","volume":"29","author":"Singh","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"18","key":"10.1016\/j.cct.2025.108075_bb0015","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cct.2025.108075_bb0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1128\/AAC.00898-06","article-title":"Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis","volume":"51","author":"Ibrahim","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.cct.2025.108075_bb0025","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1164\/rccm.201103-0397OC","article-title":"Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection","volume":"184","author":"Zhang","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.cct.2025.108075_bb0030","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"11","key":"10.1016\/j.cct.2025.108075_bb0035","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1128\/AAC.00934-10","article-title":"Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis","volume":"54","author":"Andries","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.cct.2025.108075_bb0040","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/AAC.05293-11","article-title":"Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis","volume":"55","author":"Tasneen","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.cct.2025.108075_bb0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1164\/rccm.201212-2328OC","article-title":"Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis","volume":"188","author":"Ahmad","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.cct.2025.108075_bb0050","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1128\/AAC.47.2.653-657.2003","article-title":"Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis","volume":"47","author":"Hu","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.cct.2025.108075_bb0055","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1128\/AAC.00250-06","article-title":"Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol","volume":"50","author":"Malik","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.cct.2025.108075_bb0060","doi-asserted-by":"crossref","first-page":"e0239821","DOI":"10.1128\/aac.02398-21","article-title":"Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and\/or OPC-167832 in murine tuberculosis models","volume":"66","author":"Tasneen","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"17","key":"10.1016\/j.cct.2025.108075_bb0065","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.cct.2025.108075_bb0070","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.cct.2025.108075_bb0075","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cct.2025.108075_bb0080","first-page":"953","article-title":"Biased coin design with imbalance tolerance","volume":"15","author":"Yung-Pin","year":"1999","journal-title":"Commun. Stat. Stoch. Models."},{"issue":"12","key":"10.1016\/j.cct.2025.108075_bb0085","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S2213-2600(19)30366-2","article-title":"Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial","volume":"7","author":"Tweed","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"11","key":"10.1016\/j.cct.2025.108075_bb0090","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00463-19","article-title":"Daily dosing for Bedaquiline in patients with tuberculosis","volume":"63","author":"Salinger","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.cct.2025.108075_bb0095","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bcp.14199","article-title":"Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis","volume":"86","author":"Tanneau","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.cct.2025.108075_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01207-20","article-title":"Cumulative fraction of response for once- and twice-daily Delamanid in patients with pulmonary multidrug-resistant tuberculosis","volume":"65","author":"Mallikaarjun","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.cct.2025.108075_bb0105","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5588\/ijtld.10.0616","article-title":"Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients","volume":"15","author":"Diacon","year":"2011","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"4","key":"10.1016\/j.cct.2025.108075_bb0110","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dku504","article-title":"Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug","volume":"70","author":"Svensson","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.cct.2025.108075_bb0115","first-page":"e00855","article-title":"Impact of rifabutin or Rifampin on Bedaquiline safety, tolerability, and pharmacokinetics: a randomized clinical trial in healthy adult volunteers","volume":"62","author":"Healan","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.cct.2025.108075_bb0120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00490-17","article-title":"Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and -resistant tuberculosis","volume":"61","author":"Chirehwa","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.cct.2025.108075_bb0125","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1128\/AAC.05988-11","article-title":"Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis","volume":"56","author":"Sahota","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.cct.2025.108075_bb0130","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02013-2020","article-title":"Optimising pyrazinamide for the treatment of tuberculosis","volume":"58","author":"Zhang","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.cct.2025.108075_bb0135","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1164\/rccm.202206-1118OC","article-title":"A standardized approach for collection of objective data to support outcome determination for late-phase tuberculosis clinical trials","volume":"207","author":"Kurbatova","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2025.108075_bb0140","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"U.S. Department of Health and Human Services","year":"2017"},{"key":"10.1016\/j.cct.2025.108075_bb0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12916-016-0597-3","article-title":"A new trial design to accelerate tuberculosis drug development: the phase IIC selection trial with extended post-treatment follow-up (STEP)","volume":"14","author":"Phillips","year":"2016","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.cct.2025.108075_bb0150","first-page":"128","article-title":"A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"12","author":"Rustomjee","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.cct.2025.108075_bb0155","series-title":"Conference on Retroviruses and Opportunistic Infections; Boston, MA","article-title":"Efficacy of Bedaquiline, Pretomanid, Moxifloxacin & PZA (BPAMZ) against DS- & MDR-TB [abstract]","author":"Dawson","year":"2017"},{"issue":"1","key":"10.1016\/j.cct.2025.108075_bb0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.cct.2025.108075_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"Tiemersma","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2025.108075_bb0170","series-title":"Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry","author":"FDA","year":"2016"},{"issue":"1","key":"10.1016\/j.cct.2025.108075_bb0175","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/s41467-021-22833-6","article-title":"Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens","volume":"12","author":"Walter","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cct.2025.108075_bb0180","author":"Drugs WGoNT"},{"issue":"5","key":"10.1016\/j.cct.2025.108075_bb0185","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.cct.2025.108075_bb0190","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/infdis\/jis461","article-title":"Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium","volume":"206","author":"Dorman","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.cct.2025.108075_bb0195","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/rccm.200901-0078OC","article-title":"Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis","volume":"180","author":"Dorman","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.cct.2025.108075_bb0200","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial","volume":"191","author":"Dorman","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425002691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425002691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:54:33Z","timestamp":1787925273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425002691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":40,"alternative-id":["S1551714425002691"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.108075","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38\/CRUSH-TB design","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.108075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108075"}}